Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb (BMS) has received the US Food and Drug Administration (FDA) approval for the subcutaneous (SC) formulation of Orencia (abatacept) as a treatment for rheumatoid arthritis (RA) in adult patients.
Subscribe to our email newsletter
The SC formulation of Orencia is a fixed 125mg dose which can be given weekly through an injection under the skin following a single IV loading dose of approximately 10mg/kg.
In a trial, Orencia SC showed similar safety and efficacy to Orencia IV.
BMS Commercial Operations senior vice president and US, Japan and Intercontinental president Anthony Hooper said the continued development of Orencia exemplifies their focus on areas of serious diseases and biologics drug development.